



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/10

April 29, 2026

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025

In terms of Chapter XVII of the SEBI Master Circular no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025 for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, please find enclosed a quarterly certificate certifying the use of proceeds of Commercial Paper and adherence to other listing conditions, for the quarter ended March 31, 2026.

We request you to take this on record.

Thanking You.

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328
Encl: As above

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Symbol - Biocon
--	---

REF NO: ISIN CODE: As Per Annexure I

Maturity Value of CP: As Per Annexure I

Maturity Date of CP: As Per Annexure I

With reference to the above-mentioned Commercial Paper (CP) issued by Biocon Limited (the company), it is hereby certified that:

1. The CPs were issued for the purposes mentioned in Annexure I and the CP proceeds were utilized for purposes disclosed therein and the Company is in adherence to other listing conditions as mentioned in the application for listing.
2. The other conditions of the offer document and the CP issuance directions are adhered to.
3. The asset classification of fund-based facilities from bank/Financial Institutions continues to be "Standard"
4. There has been no material change in our financial status which may adversely affect the credit rating of the Commercial Paper.
5. The total issuance of CPs during the calendar year up to the quarter ended March 2026 was Rs. 200 Crores.

For Biocon Limited



Kedar Narayan Upadhye
(Chief Financial Officer)

Date: 29th April 2026

Place: - Bangalore

Annexure I

Issuer Name	Date of CP issue	ISIN No.	FV in Rs. Cr	Maturity Date of CP*	Units	End Use of Fund
Biocon Limited	22/12/2025	INE376G14040	1800	20/03/2026	36000	Acquisition of equity shares in Subsidiary
Biocon Limited	02/01/2026	INE376G14057	200	03/03/2026	4000	Redemption of debentures issued by company and acquisition of debentures issued by subsidiary

**The Company has fully bought-back and fulfilled its payment obligation for both the CPs on 30/01/2026.*

Re